RxDoctor Payments Data

Hanna Kackielo, MD

Internal Medicine · Norwich, CTNPI 1598714701

Payments from drug & device makers

$1,229in general payments, 2019–2025

Across 77 payments — averaging $15.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$281
  • AstraZeneca$242
  • GSK$231
  • Boehringer Ingelheim$222
  • Lilly USA, LLC$124
  • Johnson & Johnson$44
  • plus $85 from 4 others

What the payments were for

  • Food & beverage$1,13092%
  • Education$998%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,229 in reported general payments places this provider in the 80th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$214,327
Medicare patients
381
Services billed
2,988

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin129$146,744
OzempicSemaglutide74$84,759
JanuviaSitagliptin Phosphate54$55,577
FarxigaDapagliflozin Propanediol40$48,266
EliquisApixaban37$43,964
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$38,942
MyrbetriqMirabegron37$26,089
XareltoRivaroxaban15$24,197
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$16,505
LinzessLinaclotide14$15,968
SynthroidLevothyroxine Sodium124$13,504
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$11,651
Tresiba Flextouch U-100Insulin Degludec13$11,018
Levothyroxine Sodium502$8,074
EdarbiAzilsartan Medoxomil11$7,771

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$222$146,744129 claims
Novo NordiskOzempic$281$84,75974 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$242$67,40769 claims
MerckJanuvia$17$55,57754 claims
GSKTrelegy Ellipta, Anoro Ellipta$231$50,59356 claims
AbbVieLinzess, Synthroid$21$29,471138 claims
Astellas Pharma US IncMyrbetriq$22$26,08937 claims
Johnson & JohnsonXarelto$44$24,19715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Norwich

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →